Peter Leif Bergsagel

This study identifies Menin as a key regulator of oncogenic gene expression in multiple myeloma and shows that Menin inhibitors are effective in myeloma cell lines and models.

This study links germline variation to tumor evolutionary dynamics in multiple myeloma, identifying TBKBP1 as a mediator of subclonal expansion and clinical outcomes.

TEATIME estimates evolutionary parameters and fitness diversity from bulk sequencing data, revealing patterns of intratumor heterogeneity across 33 cancer types.

The paper identifies genomic and transcriptional changes in multiple myeloma cells that drive resistance to anti-BCMA therapies, termed 'plasma cell identity escape'.

This study shows that administering Prevotella melaninogenica to mice with multiple myeloma delays disease progression and enhances the efficacy of PD-1/PD-L1 blockade while reducing toxicity.

This study identifies biallelic CD38 loss as a mechanism of resistance to anti-CD38 antibodies in multiple myeloma, with specific mutations affecting antibody efficacy.